Drug intelligence / Profile preview

S-488410

Development stage
Phase 2
Lead developer
Shionogi
Modality
Vaccines & Immunotherapeutics, Peptides
Administration
Subcutaneous
01

Overview

S-488410 is an investigational, HLA-A*2402-restricted therapeutic multipeptide cancer vaccine developed from three tumor-associated cancer-testis antigens: URLC10, CDCA1, and KIF20A. The fixed peptide cocktail is intended to prime antigen-specific cytotoxic T-lymphocyte responses against tumor cells that express these antigens. It was studied by subcutaneous administration in patients with advanced non-small cell lung cancer and in advanced or recurrent esophageal squamous cell carcinoma. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01592617))

Other names
HLA-A*2402-restricted multipeptide vaccine S-488410S 488410S488410S-488410
02

Targets

HLA-A*24 (Major histocompatibility complex class I molecule presenting MAGE-A4 peptide)T-cell receptor (TCR) recognizing S-488410 peptide–HLA-A*24:02 complexesKIF20A (Kinesin family member 20A)LY6K (Lymphocyte antigen 6 complex locus protein K)NDC80 (NDC80 kinetochore complex component)

Beyond the preview

Go deeper on S-488410.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-488410.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call